Jazz Pharmaceuticals (JAZZ) PT Raised to $225 at Barclays
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $108.32 -1.23%
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 2
Rating Summary:
31 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 3 | New: 2
Join SI Premium – FREE
Barclays analyst Balaji Prasad raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $225.00 (from $205.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Meta Platforms Inc. (META) PT Lowered to $500 at Goldman Sachs, 'Management Track Record of Execution Leaves Us Long-Term Constructive'
- Air Liquide SA (AI:FP) (AIQUY) PT Raised to EUR210 at Berenberg
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
